Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
NEW YORK, Sept. 06, 2017 -- Shepherd, Finkelman, Miller & Shah, LLP (“SFMS”) announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey (Civil Action No. 17-06454) against Vitamin Shoppe, Inc. (“Vitamin Shoppe” or the “Company”) (NYSE:VSI) and certain of its officers and directors. The case seeks remedies under the Securities Exchange Act of 1934 and is brought on behalf of a class consisting of all persons or entities that acquired Vitamin Shoppe securities between March 1, 2017 and August 6, 2017, inclusive (the “Class Period”). If you would like to discuss this action or have any questions regarding this notice or your rights, please contact either Bruce Parke ([email protected]) or Jonathan Dilger ([email protected]); (866) 540-5505.
The Complaint alleges that, throughout the Class Period, Vitamin Shoppe made false and/or misleading statements and/or failed to disclose that: (1) the Company’s retail segment was suffering a severe decline due to a lack of success with its ongoing reinvention strategy; (2) changes to the Company’s operating plan had rendered the more than $168 million in goodwill being carried on Vitamin Shoppe’s books for the retail segment impaired; (3) the Company inappropriately delayed recognizing the impairment charge; and (4) as a result, defendants’ public statements about the Company’s financial prospects and the success of its reinvention plan were materially false and misleading at all relevant times.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN AN ATTORNEY. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS TIME. If you purchased or otherwise acquired Vitamin Shoppe securities during the Class Period, we encourage you to contact us with any questions prior to the October 27, 2017 lead plaintiff motion deadline.
SFMS is recognized as an accomplished firm in the areas of securities, corporate governance, antitrust and employee benefits litigation with offices in California, Connecticut, Florida, New Jersey, New York and Pennsylvania, as well as affiliate offices in London, England, and Milan, Italy. SFMS has recovered hundreds of millions of dollars on behalf of investors. For more information, please visit us at http://www.sfmslaw.com.
Contacts: Bruce Parke Jonathan Dilger Shepherd Finkelman Miller & Shah, LLP www.sfmslaw.com Telephone: (866) 540-5505 Email: [email protected] [email protected]
